secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001641172-25-020847
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment
--------------------------------------------------------------------------------

- All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.
- Ratification of Weinberg & Company as FY 2025 auditor passed: 1.79M for, 59K against.
- Non-binding advisory vote on executive compensation approved: 1.17M for, 20K against.
- Approved issuance of up to 19.99% of outstanding common stock related to May 2025 purchase agreements and convertible preferred.
- Amendment No. 1 to 2022 Omnibus Incentive Plan, increasing shares by 583,334, approved: 1.15M for, 35K against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000164117225020847/0001641172-25-020847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000164117225020847/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-020847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer